Provided by Tiger Trade Technology Pte. Ltd.

T. Rowe Price Health Care ETF

33.37
+0.15230.46%
Volume:1K
Turnover:49.55K
Market Cap:32.54M
PE:- -
High:33.59
Open:33.59
Low:33.37
Close:33.22
52wk High:36.72
52wk Low:27.57
Shares:975.00K
Float Shares:975.00K
Volume Ratio:1.17
T/O Rate:0.15%
Dividend:0.16
Dividend Rate:0.49%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Gilead Sciences Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Gilead put volume heavy and directionally bearish

TIPRANKS
·
Oct 01

Judge Denies In Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
Oct 01

Judge Denies in Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Abbott Launches SimpleScreen Blood Test for Colorectal Cancer

MT Newswires Live
·
Sep 30

Abbott to Release Q3 2026 Results, Host Earnings Call

Reuters
·
Sep 30